Update on biomarkers in neuromyelitis optica

GJCFICC&BR

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    Abstrakt

    Neuromyelitis optica (NMO) (and NMO spectrum disorder) is an autoimmune inflammatory disease of the CNS primarily affecting spinal cord and optic nerves. Reliable and sensitive biomarkers for onset, relapse, and progression in NMO are urgently needed because of the heterogeneous clinical presentation, severity of neurologic disability following relapses, and variability of therapeutic response. Detecting aquaporin-4 (AQP4) antibodies (AQP4-IgG or NMO-IgG) in serum supports the diagnosis of seropositive NMO. However, whether AQP4-IgG levels correlate with disease activity, severity, response to therapy, or long-term outcomes is unclear. Moreover, biomarkers for patients with seronegative NMO have yet to be defined and validated. Collaborative international studies hold great promise for establishing and validating biomarkers that are useful in therapeutic trials and clinical management. In this review, we discuss known and potential biomarkers for NMO.

    OriginalsprogEngelsk
    Artikelnummere134
    TidsskriftNeurology: Neuroimmunology and NeuroInflammation
    Vol/bind2
    Udgave nummer4
    DOI
    StatusUdgivet - 1 jan. 2015

    Fingeraftryk Udforsk hvilke forskningsemner 'Update on biomarkers in neuromyelitis optica' indeholder.

    Citationsformater